Trial Profile
A Phase I/II Clinical Trial of the Anti-EGFR Monoclonal Antibody, Panitumumab, and the Proteosomal Inhibitor, Bortezomib, in Patients With Advanced, Refractory KRAS Wild-Type Colorectal Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Panitumumab
- Indications Colorectal cancer
- Focus Adverse reactions
- 12 Feb 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 09 Jan 2012 New trial record